DaVita Inc. stock holds steady as BofA lifts price target to USD 180
Published on 09/14/2026 at 16:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
DaVita Inc. stock (ISIN US23918K1088) ended the last completed NYSE session on September 11, 2026 at USD 181.55, edging down 0.01 percent from its previous close and broadly matching the wider market performance that day. According to MarketScreener on September 14, 2026, Bank of America has increased its price target on DaVita Inc. stock to USD 180 from USD 170, highlighting a more constructive stance on the dialysis provider.
Price level and technical backdrop
Per NYSE quote data for September 11, 2026, DaVita Inc. stock closed that session at USD 181.55, representing a marginal 0.01 percent decline versus the previous day and leaving the shares trading close to the middle of their intraday range, as reported in a recent market summary. The same overview notes that trading volume on September 11, 2026 stayed within a typical band for the stock, suggesting limited repositioning ahead of the new week and underscoring that the modest move came without heavy turnover.
A technical review from FXEmpire based on data as of September 11, 2026 shows DaVita Inc. trading around USD 181.55, with key short-term moving averages such as the 10-day simple moving average near USD 180.38 and the 20-day simple moving average around USD 178.90. In contrast, longer-term measures like the 50-day simple moving average at roughly USD 205.06 indicate that the current price is still below levels seen earlier in the period, underlining that the stock remains beneath its recent medium-term trend even as shorter-term momentum has started to turn up.
BofA price target move and earnings context
The latest notable catalyst for DaVita Inc. stock comes from Bank of America, which, according to MarketScreener on September 14, 2026, has raised its price target on DaVita Inc. from USD 170 to USD 180. The move represents an increase of USD 10, or about 5.9 percent, and brings the fresh target close to the current share price region, suggesting that the bank views the stock as fairly valued with limited but positive upside based on its latest assessment.
DaVita Inc. is a leading provider of dialysis services in the United States, and recent analyst commentary broadly reflects the company’s defensive characteristics in healthcare, though the precise rating associated with the Bank of America target change was not detailed in the MarketScreener note. For investors, the key takeaway from the new USD 180 price target is that a major Wall Street bank has become slightly more optimistic on the stock compared with its prior USD 170 view, even as the shares currently trade a little above that revised target level.
Stock positioning versus recent trend
From a chart perspective, DaVita Inc. stock’s level around USD 181.55 as of September 11, 2026 places it below the 50-day simple moving average cited at about USD 205.06 in the FXEmpire technical analysis, a gap of roughly USD 23.51 that signals the shares are trading beneath their medium-term trend line despite the recent stabilization. At the same time, shorter-term signals such as the 10-day and 20-day moving averages near USD 180.38 and USD 178.90, respectively, sit just below the current price, indicating that the stock has started to find support above those shorter-term reference points.
FXEmpire’s technical overview for September 11, 2026 characterizes oscillators as showing buying pressure while moving averages on the daily timeframe remain largely bearish, resulting in an overall neutral signal for DaVita Inc. stock. This combination of indicators suggests that the longer-term trend still points lower but short-term momentum is turning up, an environment in which new fundamental news such as the Bank of America price target increase can play an outsized role in shifting investor sentiment.
Closing price snapshot
At the NYSE close on September 11, 2026, DaVita Inc. stock traded at USD 181.55, with the 0.01 percent daily decline underlining a largely unchanged session that left the shares close to the central area of their recent trading range. For retail investors, the latest Bank of America move to lift the price target from USD 170 to USD 180 as reported on September 14, 2026 provides an updated reference point for how one major analyst house currently values the dialysis specialist relative to where the stock is changing hands on the exchange.
DaVita Inc. stock facts
- Company: DaVita Inc.
- ISIN: US23918K1088
- Ticker: DVA
- Trading venue: NYSE
- Price (as of September 11, 2026): 181.55 USD
- Sector / Industry: Health Care / Health Care Providers & Services
- Index membership: S&P 500
